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Abstract 
The ultimate goal of calibrated fMRI is the quantitative imaging of oxygen metabolism 
(CMRO2), and this has been the focus of numerous methods and approaches. However, one 
underappreciated aspect of this quest is that in the drive to measure CMRO2, many other 
physiological parameters of interest are often acquired along the way. This can significantly 
increase the value of the dataset, providing greater information that is clinically relevant, or 
detail that can disambiguate the cause of signal variations. This can also be somewhat of a 
double-edged sword: calibrated fMRI experiments combine multiple parameters into a 
physiological model that requires multiple steps, thereby providing more opportunity for error 
propagation and increasing the noise and error of the final derived values. As with all 
measurements, there is a trade-off between imaging time, spatial resolution, coverage, and 
accuracy. In this review, we provide a brief overview of the benefits and pitfalls of extracting 
multiparametric measurements of cerebral physiology through calibrated fMRI experiments. 
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Abbreviations 
AAT             Arterial arrival time 
AD               Alzheimer’s disease 
ASL             Arterial spin labelling 
BOLD          Blood oxygenation level dependent 
CBF             Cerebral blood flow 
CBV             Cerebral blood volume 
CMRO2       Cerebral metabolic rate of oxygen 
CT                Computed tomography 
CVR            Cerebrovascular reactivity 
dHb             Deoxyhaemoglobin 
DOT  Diffuse Optical Tomography 
DSC            Dynamic susceptibility contrast 
EEG             Electroencephalography 
EPI               Echo planar imaging 
FiCO2          Inspired fraction of carbon dioxide 
FiO2             Inspired fraction of oxygen 
fMRI             Functional magnetic resonance imaging 
Hb                Haemoglobin 
Hct               Haematocrit 
LDF  Laser Doppler Flowmetry 
MEG  Magnetoencephalography 
OEF             Oxygen extraction fraction 
PaO2            Arterial partial pressure of oxygen 
PaCO2            Arterial partial pressure of carbon dioxide 
pCASL        Pseudo-continuous arterial spin labelling 
PET             Positron emission tomography 
PETO2           End tidal partial pressure of oxygen 
PETCO2           End tidal partial pressure of carbon dioxide 
PLD             Post-label delay 
PO2              Partial pressure of oxygen 
SaO2            Arterial saturation of oxygen 
SNR            Signal to noise ratio 
SPECT        Single photon emission tomography 
SvO2            Venous saturation of oxygen 
TCD             Transcranial Doppler ultrasound 
TRUST T2 Relaxation Under Spin Tagging 
VASO          Vascular space occupancy 
vCBV           Venous cerebral blood volume 
VERVE       Venous refocusing for volume estimation 
 
 
1.      Introduction 
  
Functional MRI is dominated by blood oxygenation level dependent (BOLD) imaging of 
changes in the gradient echo signal during a task or stimulus, which provides robust sensitivity 
to local haemodynamic changes and can be easily implemented in most clinical and research 
scanners. It has proven to be a powerful tool for localising activity in the brain, and has 
revolutionised neuroimaging (Bandettini, 2012). Despite the physiological origins of the BOLD 
signal, it is not a pure or quantitative signal; BOLD contrast is driven by relative changes in 
more than one physiological parameter, and thus dependent on both baseline physiology and 
the magnitude of any neurovascular changes.  If we wish to know more than simply the 
location of functional activity in the brain, to compare activation between sessions, subjects, 
scanners or sites, or to account for the effects of interventions on brain function, then BOLD 
fMRI alone is not sufficient. To address these aims, we can employ additional imaging 
contrasts and models of human physiology and MRI physics to “calibrate” the BOLD fMRI 
signal, resulting in a meaningful physiological parameter that reflects specific aspects of brain 
function in health or disease. 
 
The ways in which such calibration experiments have been implemented over the last 20 years 
have evolved (see article by Gauthier et al. in this issue), but the goal of obtaining quantitative 
physiological images remains the same, primarily focussing on the quantification of changes 
in the cerebral metabolic rate of oxygen consumption (CMRO2). Importantly, all variants 
require the collection of additional imaging data beyond BOLD-weighted scans, which may 
provide valuable insight into physiological processes by themselves, or through combined 
modelling. In this way, calibrated fMRI experiments provide a framework for extended 
multiparametric physiological imaging. Rather than only considering the endpoint of the 
calibration process, i.e. CMRO2, the extra effort required for acquiring and analysing a 
calibrated fMRI dataset can be justified by the added value of the numerous distinct 
physiological parameters that are extracted. A compound parameter such as the BOLD signal 
is difficult to interpret when dealing with patients, subjects with comorbidities, different 
treatment arms in clinical trials, pharmacological interventions, and natural variations in 
physiology between individuals. By obtaining a richer dataset along the road to calibration, 
there is a greater chance of determining the mechanisms of action in disease and comparing 
like-for-like in specific patient cohorts, thus enabling more complex questions to be 
considered. 
  
In this paper, we describe each parameter that can be acquired or derived in a calibrated fMRI 
experiment designed either to provide a relative change in a physiological parameter during 
some period of elevated brain activity, or a baseline value at rest. The gas challenges utilised 
for calibration have direct, unintended consequences on the imaging data, and it is important 
to adjust scanning and analysis protocols to minimise or account for these effects. However, 
despite these challenges, the resulting diversity in physiological information adds immensely 
to our understanding of brain function and neurological disease. 
 
 
2.      Calibrated fMRI 
  
The most successful approach for modelling the BOLD signal in terms of physiological 
parameters was first presented by Davis et al. (1998), and later refined by Hoge et al. (1999). 
These models express a BOLD signal change in response to a stimulus or task in terms of 
relative changes in cerebral blood flow (CBF), cerebral blood volume (CBV) and CMRO2. 
Written out in its full form, and shown schematically in Figure 1, the BOLD signal can be shown 
to be a function of these haemodynamic and metabolic changes scaled by M, the BOLD 
calibration constant.  
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Here, physiological parameters during the active or stimulated state (e.g., CBV) are 
normalised by their value at baseline (e.g., CBV0). The exponent β controls for the effect of 
vessel size on the acquired data (Ogawa et al., 1993). Section 4.3 details the origin of β and 
the appropriate selection of its value. As discussed in greater detail in subsequent sections, 
CBV changes are rarely imaged directly in calibrated fMRI; instead they are inferred from 
changes in CBF, which is more easily measured using Arterial Spin Labeling (ASL) techniques 
(see section 3.2). This interaction between CBF and CBV (as shown in Figure 1) is described 
by a model of CBF-CBV coupling and characterised by the constant α, selection of which is 
covered in section 4.2. 
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In order to estimate changes in CMRO2, measurements of the changes in the BOLD signal 
and CBF are required, as well as the BOLD calibration constant, M. Unlike BOLD and CBF, 
M is not directly measured, rather it is estimated through a calibration experiment. This 
experiment involves the administration of air with either added carbon dioxide (CO2) or an 
increased oxygen (O2) content, and is described in further detail in the next section. However, 
by acquiring these additional measurements it is possible to extract specific physiological 
information (namely CMRO2) from the otherwise complex haemodynamic and metabolic 
contributions to the BOLD signal.  
 
Calibrated fMRI has historically focussed on the measurement of relative changes in CMRO2 
due to brain activity. However, more recently this technique has been extended to baseline 
measurements of CMRO2, reflecting the activity of the brain at rest. This new group of 
techniques was developed nearly simultaneously by three research groups (Bulte et al., 2012; 
Gauthier and Hoge, 2012a; Wise et al., 2013). In contrast to conventional calibrated fMRI, 
these techniques aim to separate the contributions to M, rather than just account for its effect 
on the BOLD signal (see Figure 1). By considering the derivation of Eq. (1), the sensitivity of 
the BOLD signal to baseline blood oxygenation (or more specifically deoxygenation) can be 
observed. 
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Here, [dHb]0 is the concentration of deoxyhaemoglobin (dHb) in venous blood vessels at rest 
and Δ[dHb] is the change in dHb concentration during the calibration step. Since [dHb]0 is a 
function of venous blood oxygen saturation, it can be used to calculate the oxygen extraction 
fraction (OEF) and, in combination with baseline CBF, baseline CMRO2 can be calculated. 
However, we are now left with two unknowns; M and Δ[dHb]. The solution to this problem is 
to perform two calibration experiments: the first to estimate M and the second where Δ[dHb] 
can be modelled accurately by using a stimulus that has a well characterised effect on blood 
oxygenation. Therefore, we will refer to this group of techniques for measuring baseline OEF 
and CMRO2 as dual calibrated fMRI. 
 
The calibration experiment is important to both conventional calibrated fMRI and dual 
calibrated fMRI. The stimulus for this calibration generally consists of gas inhalation and will 
be considered in the following section. There is also the prospect of gas free calibration, which 
is considered in section 7.2. 
  
 
Figure 1. The Davis model describes the major physiological drivers of changes in the 
BOLD signal. BOLD signal changes can be driven by stimulus-related changes in CBF, 
CBV and CMRO2. Gas stimuli, such as a hypercapnia challenge, may impact CBF and 
CBV without altering baseline CMRO2, and additional imaging data can be acquired to 
estimate these dynamic changes in CBF, CBV, or both. However, knowledge of changes 
in haemodynamics and oxygen metabolism are not sufficient to describe the magnitude 
of the BOLD signal change: baseline physiological parameters such as OEF and CBV 
determine the maximum BOLD signal change and hence the scaling of the BOLD 
response (via the BOLD calibration constant, M). 
 
  
2.1  Calibration via gas inhalation challenges 
 
Gas inhalation has been used since the earliest days of fMRI to normalise the BOLD signal 
(Bandettini and Wong, 1997). Initially this consisted of a brief period of hypercapnia via an 
increased inspired fraction of CO2. This gas challenge was used to induce an isometabolic 
increase in CBF, thereby reducing OEF and increasing the BOLD signal. It remains 
controversial whether gas challenges can be considered truly isometabolic in these 
experiments (see Section 4.5 for further discussion). However, by making this assumption, 
Eq. 2 can be used to estimate M when combined with measurements of CBF and BOLD (see 
section 4.4 for details).  
 
Following the same principle, hypercapnia calibration was later followed by hyperoxia 
calibration, which is induced by administration of air with an increased O2 fraction. By 
assuming isometabolism, Eq. 3 can be used to estimate M by combining CBV (inferred from 
CBF measurements) and BOLD data with oxygen transport modelling to estimate Δ[dHb] 
(Chiarelli et al., 2007). Similarly to hypercapnia, there has been some controversy over 
whether hyperoxia is truly isometabolic (see Section 4.5). Further details on the 
implementation of hyperoxia calibration can be found in Section 4.4. 
 
Administration of hypercapnic and hyperoxic gas mixtures follow common approaches. The 
earliest, and most simplistic, approaches utilised a Douglas bag pre-filled with a fixed gas 
content (known as a fixed inspired challenge), which was switched with room air using a 
manifold and inhaled through a closed breathing mask (Douglas and Haldane, 1905). These 
techniques have been supplemented by potentially more accurate and repeatable (Fisher, 
2016) automated gas delivery systems based on feed-forward (Prisman et al., 2008) or feed-
back algorithms (Wise et al., 2007). Choice of gas delivery should be informed by budgetary 
constraints, patient comfort and stimulus accuracy and repeatability requirements. 
 
 
3.      Acquired measurements 
  
3.1   BOLD 
  
As indicated in Figure 1, the BOLD signal is the product of complex and coupled changes in 
multiple vascular and metabolic factors, and can be additionally modulated via pulse sequence 
parameters used in scanning. As such, the baseline BOLD-weighted signal is without direct 
physiological interpretation. However, BOLD fMRI, where changes in BOLD-weighted signals 
are sampled, remains the dominant workhorse of the neuroimaging field for good reasons: it 
has high SNR, is extremely sensitive to changes in oxygenation, can be sampled with rapid, 
high-resolution acquisition schemes, and ultimately allows for exquisite characterisation of 
subtle changes in brain activity. 
 
Whilst the BOLD effect was first demonstrated in 1990 (Ogawa et al., 1990), the background 
to understanding its origin had largely already been discovered. NMR experiments in the 
1980’s revealed that the transverse relaxation time, T2, of blood was oxygenation dependent 
(Thulborn et al., 1982). Hence, the increased blood oxygenation observed by Ogawa and 
colleagues in their hypercapnia experiments resulted in an increase in T2 and the 
disappearance of the venous blood vessels that had appeared as dark lines during air 
breathing. However, this intravascular effect is dependent on the blood volume, which makes 
up only a small fraction of the tissue volume, and so a second mechanism was hypothesised 
to contribute to the blooming of the venous vessels. This mechanism is based on the magnetic 
susceptibility of haemoglobin, which was discovered in 1936 (Pauling and Coryell, 1936). 
Importantly, it was the compartmentalisation of this susceptibility within venous blood vessels, 
and its relative paramagnetism with respect to the surrounding tissue, that resulted in an 
extravascular contribution to the BOLD effect (Ogawa et al., 1993). Protons in the tissue 
surrounding deoxygenated blood vessels experience the magnetic field gradients generated 
by this susceptibility difference resulting in dephasing of the magnetisation and an 
enhancement of the transverse relaxation time known as T2*.  
 
Despite this explanation of the BOLD effect, it wasn’t entirely clear that this would be useful 
for mapping brain activity. It is widely known that CBF and CMRO2 are tightly coupled during 
baseline and it was anticipated that during increased brain activity this would be maintained. 
Under these conditions, blood oxygenation would be unchanged and the BOLD effect would 
be blind to changes in brain activity. Fortunately, results from Positron Emission Tomography 
(PET) had revealed a focal uncoupling of CBF and CMRO2 during sensory stimulation in the 
years preceding the discovery of the BOLD effect (Fox and Raichle, 1986). The implication of 
this is that during focal brain activity changes in CBF exceed changes in CMRO2, resulting in 
a decreased OEF, increased blood oxygenation and an increase in the BOLD signal. However, 
as Eq. 3 makes clear, the changes in the BOLD signal do not result purely from changes in 
the blood oxygenation (described as changes in [dHb]), but also depend on changes in CBV. 
As such, changes in the BOLD signal can be considered proportional to the absolute change 
in dHb content and M as being proportional to the dHb content of the voxel at rest. 
  
When BOLD contrast was first explored in the early 1990’s, echo planar imaging (EPI) 
(Mansfield, 1977) enabled rapid acquisition of T2*-weighted contrast, achieving temporal 
resolutions sufficient to resolve functional changes in blood oxygenation (2-3.5 s) (Bandettini 
et al., 1992; Belliveau et al., 1992; Kwong et al., 1992). Most BOLD fMRI experiments today 
follow very similar practices to these early studies, although higher field strengths, advances 
in scanner hardware, new acceleration techniques, and novel read-out strategies have 
improved data quality, enabling faster scanning of higher resolution data with better stability, 
and higher SNR and CNR. For example, large multi-centre initiatives, such as the Human 
Connectome Project, routinely collect BOLD-weighted fMRI data using multiband pulse 
sequences to achieve whole-brain coverage with 2mm isotropic voxel resolution in just 700ms 
(Van Essen et al., 2013). 3D-EPI techniques may achieve similar resolutions with even higher 
SNR (Stirnberg et al., 2017). It remains to be seen how these exciting advances in BOLD-
weighted acquisition techniques, which are being adopted widely across the fMRI community, 
will be implemented in the context of calibrated fMRI. 
  
  
3.2   CBF 
  
Since the original work by Davis et al. (1998) the most prevalent secondary measurement 
used to calibrate the BOLD signal has been CBF. This was originally a measure of the relative 
change in CBF due to a hypercapnic stimulus using a Flow-Sensitive Alternating Inversion 
Recovery (FAIR) spin echo pulsed arterial spin labelling (PASL) sequence in a separate scan, 
but was rapidly advanced to an interleaved technique to enable simultaneous measurement 
of the BOLD and flow responses (Hoge et al., 1999). 
  
As advances in CBF imaging using MRI were made, these were incorporated into calibration 
methods in order to improve coverage, resolution, speed and accuracy, while the BOLD 
imaging remained essentially unchanged. Initially this was by replacing the FAIR sequence 
with QUIPSS II (Wong et al., 1998) or Q2TIPS (Luh et al., 1999) in order to reduce errors due 
to transit time delays, and also enable a degree of absolute flow quantification. The technique 
also moved from single slices to multi-slice images, initially 5 to 8 slices at 5 to 7mm thick. 
This heralded somewhat of a golden age for calibrated fMRI. Interleaved sequences were 
replaced with dual-echo ones to dramatically increase temporal resolution and thus improve 
fitting statistics. Later, image read-out options were further expanded as the dual-echo 
approach was refined to the double excitation (DEXI) method, which improved the SNR for 
combined BOLD and ASL approaches, and reduced cross-contamination of the signals 
(Schmithorst et al., 2014). 
  
The rise in popularity of pseudo-continuous ASL (pCASL) sequences was a watershed 
moment for ASL (Dai et al., 2008); these sequences offered an increase in SNR that enabled 
higher spatial resolution and greater brain coverage. Techniques for acquiring pCASL data 
with multiple post-label delays (PLDs) allowed more accurate quantitative CBF maps using 
the Buxton model (Richard B Buxton et al., 1998), comparing favourably to 15O-PET CBF 
measurements (Zhang et al., 2014), and facilitating the estimation of regional arterial arrival 
time (AAT) changes during hypercapnia. Initially greeted with enthusiasm by those seeking 
calibration, there quickly came a note of warning: although pCASL was apparently superior 
for quantitative measurement of resting CBF or changes in CBF during sensory stimuli or 
cognitive tasks, an additional (and important) confound occurs during calibrated fMRI with gas 
challenges. pCASL sequences rely on inverting spins in a thin tagging plane below the imaging 
volume. Due to thermodynamics, and as the spins are moving through this plane with varying 
velocities during the cardiac cycle, the efficiency of this inversion is not 100%. It is generally 
assumed that the inversion efficiency is approximately 85-95% (Juttukonda et al., 2017; 
Mezue et al., 2014). The effect of a global vasodilatory stimulus such as hypercapnia is a 
significant increase in the flow velocity through the major feeding arteries such as the internal 
carotid and vertebral arteries. This results in a significant reduction in the inversion efficiency 
(Aslan et al., 2010), which would need to be measured and taken into account in order to 
maintain accuracy when comparing pCASL results during hypercapnia and at baseline (Chen 
et al., 2017). Furthermore, the inversion efficiency is unlikely to be the same in each of the 
four main neck arteries, as the carotids are generally wider than the vertebrals, and there is 
often a significant disparity in diameter between the two vertebrals themselves. The relative 
change in inversion efficiency during gas challenges is thus also likely to vary between 
arteries, impacting the CBF values measured in their respective territories (Berry et al., 2015). 
Flow velocity in large arteries may also influence the regional AAT of the labelled blood in 
downstream tissue. 
  
There are multiple variants of the pCASL sequence that have their own intrinsic behaviours, 
and are impacted differently by the choice of sequence parameters, labelling planes, and gas 
stimuli. Fundamentally, a pCASL sequence may be either balanced or unbalanced, which can 
have a significant impact on the labelling efficiency due to B0 inhomogeneity (Jahanian et al., 
2011; Wu et al., 2007). Numerous labelling and read-out parameters may vary between 
pCASL implementations, including the labelling pulse shape, mean labelling gradient, 
maximum labelling gradient, labelling flip angle, labelling duration, initial post-label delay, 
labelling position, readout approach, number of slices, slice thickness, matrix size, field of 
view, fat suppression, parallel imaging, B1-filtering, partial Fourier, background suppression, 
vascular suppression, and number of label-control pairs (Mutsaerts et al., 2015). There are 
steps that can be taken to minimise the impact of the choice of pCASL sequence and 
parameters on the CBF measurement (Zhao et al., 2016), and care must be taken with these. 
A recent multi-vendor study testing reproducibility noted: “Small differences in sequence 
parameters can have a larger effect on the reproducibility of ASL than hardware or software 
differences between vendors.” (Mutsaerts et al., 2015). 
  
In light of these issues, a consensus has yet to be formed as to which is the optimal approach 
for measuring changes in CBF for calibration purposes. Considering the sensitivity of pCASL 
to arterial flow velocities and arrival times, it may be that although pCASL is superior for 
measuring CBF in general, it is PASL, with its relative insensitivity to bulk changes in flow 
within the labelling region, which is a better choice for calibration. 
  
3.3   CBV 
  
Whilst CBF is the most common secondary measurement used to calibrate the BOLD 
response, it is also important to account for the effect of stimulus induced changes in CBV. In 
conventional calibrated fMRI, following the Davis model (described in Section 2), this is 
achieved by using a measurement of the change in CBF (from an ASL acquisition) as a proxy 
for changes in CBV. The relationship between these parameters can be described by the well-
established power law relationship (CBV ∝	CBFα), where the exponent is commonly known as 
the Grubb constant (Grubb et al., 1974). In this work, a value of α = 0.38 was measured for 
the change in CBV across all vascular compartments (arterial, capillary and venous), 
otherwise known as total CBV (See Section 4.2 for more detailed discussion of α). 
  
However, in order to accurately model the effect of changes in CBV on the BOLD response, 
it is important to understand the physiology that underlies BOLD contrast. In the early days of 
(uncalibrated) BOLD fMRI it was assumed that the majority of the change in CBV during 
“activation” was localised to the venous blood vessels (Buxton et al., 1998; Mandeville et al., 
1999). However, it became clear that this was not the case, and that the change in CBV is 
much larger in arterial vessels (Lee et al., 2001). For healthy human subjects, blood within the 
arterial vessels has an oxygen saturation approaching 100%. As the BOLD response is largely 
dependent on changes in the deoxyhaemoglobin content of the voxel, we do not anticipate a 
meaningful contribution to the BOLD signal from arterial vessels. Therefore, the relevant 
change in CBV for calibrated fMRI is not the large arterial dilation, but rather the small fraction 
of the total CBV change that originates from the veins and capillaries. Incorporating this 
understanding of the physiology into the acquisition and analysis of calibrated fMRI data is 
important to minimise systematic error, and techniques to measure the change in venous CBV 
are required to enable more accurate estimation of α, or to incorporate directly in the 
estimation of CMRO2. 
  
One such method, known as the venous refocusing for volume estimation (VERVE) technique, 
specifically measures changes in venous CBV (Stefanovic and Pike, 2005). The VERVE 
technique works by applying a train of refocusing pulses to recover signal lost to the dephasing 
effect of deoxygenated blood. Venous blood can be isolated by altering the inter-pulse 
spacing, which results in additional signal loss in deoxygenated blood but leaves oxygenated 
blood unaffected. By combining measurements of venous CBV from VERVE with ASL-based 
measurements of CBF during an fMRI stimulus paradigm, a venous specific value of α of 0.23 
has been estimated (Chen and Pike, 2009), which is now routinely used in calibrated fMRI 
experiments (Bulte et al., 2012; Gauthier and Hoge, 2012a). Unfortunately, VERVE is limited 
to a single slice acquisition, making it impractical as a means to measure venous CBV in the 
more general application of calibrated fMRI. However, by refining the estimation of α, this 
technique has played an important role in reducing systematic error in the estimation of 
stimulus-evoked changes in CMRO2. 
  
The simultaneous acquisition of changes in BOLD, CBF and CBV has been achieved by using 
the vascular space occupancy (VASO) method (Lin et al., 2008). This has the advantage that 
the resulting estimates of CBV are subject and stimulus specific, which may be important in 
applications where CBF-CBV coupling is believed to be altered (See Section 4.2 for further 
detail). The VASO technique relies on the differing longitudinal relaxation times, T1, between 
tissue and blood. By applying a global inversion pulse and imaging at the inversion time, TI, 
at which the blood signal is nulled, the signal can be sensitised to CBV. Interestingly, since 
this involves signal nulling, increases in CBV translate to decreases in the VASO signal, as a 
greater volume of blood signal is nulled. Unfortunately, there are two disadvantages to the 
VASO technique. Firstly, unlike ASL, the ratio of the activated condition to the baseline 
condition does not give a measure of the fractional change in CBV; baseline CBV must be 
known or assumed (Lu et al., 2003). Secondly, by inverting the whole blood volume, VASO is 
sensitive to total CBV rather than the venous CBV that underlies BOLD contrast. Therefore, it 
is likely to overestimate the contribution of CBV changes, which will propagate into an 
underestimation of changes in CMRO2. 
  
The estimation of venous CBV using hyperoxia follows the principles of dynamic susceptibility 
contrast (DSC) MRI; the usual Gadolinium-based contrast agent is effectively replaced by 
deoxygenated haemoglobin acting as a non-diffusible tracer. By increasing the oxygen content 
of arterial blood, largely through an increase in the oxygen content of plasma, the oxygen 
saturation of venous blood is increased. In DSC MRI, absolute CBV is measured by 
normalising signals to a voxel containing only arterial blood, referred to as the arterial input 
function (AIF). However, the signal from arterial blood is not affected by hyperoxia due to the 
oxygenation saturation being nearly 100%. Instead, the signal from the sagittal sinus (isolating 
a voxel containing only venous blood) can be used to perform a similar normalisation (Bulte 
et al., 2007b). This normalisation step aims to account for the true concentration of the contrast 
agent (or, in this case, dHb content) in the blood. A blood sample could be drawn and analysed 
for either gadolinium concentration or oxygen saturation, but this is typically undesirable due 
to the invasiveness and time-intensive nature of such a procedure. Fortunately, with a gas 
challenge such as hyperoxia, the effect on arterial gas tensions can be estimated by 
measuring the oxygen content of the subject’s expired breaths (as described in Section 4.4), 
enabling the change in arterial saturation due to the gas challenge to be calculated 
(Severinghaus, 1979). It has since been shown that the hyperoxia BOLD signal change is 
linearly dependent on PaO2 (Blockley et al., 2013). Therefore, maps of the hyperoxia BOLD 
signal change represent relative venous CBV at rest, with absolute maps generated by 
appropriate scaling. This scale factor can be calculated using a heuristic model derived from 
detailed simulations of the BOLD signal, which is a function of echo time and PaO2. A similar 
approach can be used to estimate changes in venous CBV (Blockley et al., 2012a). 
  
The use of the hyperoxia BOLD signal to measure venous CBV may seem inconsistent with 
its use to calibrate the BOLD response (Chiarelli et al., 2007). However, hyperoxia-based 
calibrated fMRI requires the baseline OEF to be assumed. Whilst this may be considered a 
limitation in the context of measuring stimulus evoked changes in CMRO2, this unknown is 
what enables dual calibrated fMRI to measure OEF. Intuitively, this can be explained as 
varying the value of OEF until the estimates of M are consistent between hypercapnia and 
hyperoxia (Gauthier and Hoge, 2012a) or by dividing out the effect of venous CBV from the 
hypercapnia M value (Blockley et al., 2015b). 
 
3.4 End-tidal gases 
  
Key to understanding the influence of the gas challenges is real-time monitoring of the 
participant’s end-tidal gas levels. End-tidal values represent the averaging of alveolar gas 
levels, and are used to represent our best approximation of PaO2 and PaCO2. As O2 and CO2 
diffuse rapidly across biological membranes, arterial partial pressures rapidly reach a steady 
state with alveolar partial pressures. However, the two spaces do not have equal partial 
pressures (i.e. PaO2 ≠ PETO2) due to the alveolar-arterial gradient (A-a gradient), which 
effectively represents the (in)efficiency of the lung surface. However, changes in end-tidal 
levels are linearly correlated with changes in arterial partial pressures. Several studies have 
demonstrated tight coupling between end-tidal and arterial values, although systematic biases 
have been reported that can be further altered by exercise or aging (Peebles et al., 2007; 
Robbins et al., 1990; Young et al., 1991). Certain methods for administering and monitoring 
gas challenges may make this relationship more accurate (Ito et al., 2008). In practice, end-
tidal values are a pragmatic and robust approach for monitoring the effects of a hypercapnic 
or hyperoxic gas challenge during scanning. 
 
  
 
4.      Assumptions, error, and variability 
 
Here we consider the compromises necessary when acquiring multiple contrasts (i.e. BOLD 
and CBF weighting) in one imaging session. We examine the meaning and derivation of model 
parameters α and β, the values typically assumed, and methods for empirically determining 
them. The BOLD scaling factor, M, is described, paying additional attention to the error and 
variability that can occur due to incorrect assumptions regarding haematocrit (Hct) and arterial 
oxygen saturation (SaO2). Finally, the Davis model assumes that the gas challenges used in 
calibration are isometabolic (do not alter CMRO2); we present the controversial findings in the 
literature regarding this fundamental assumption. 
 
4.1   Compromises in scan acquisition 
  
The requirement to obtain multiple, distinct image contrasts concurrently in one scan inevitably 
results in less optimal individual images than if each were collected in isolation. Trade-offs are 
necessary, selecting temporal resolution, spatial resolution, voxel size, brain coverage, and 
echo time values that enable sufficient SNR across all acquired image parameters. Several 
examples of concurrent acquisition techniques have already been described above. 
  
Obtaining BOLD signal by adding together ASL image pairs requires using a TE that is 
suboptimal for either BOLD, ASL, or both. Interleaving ASL and BOLD acquisitions has very 
poor temporal resolution, due to the post-label delay of the ASL acquisition and need for pairs 
of labeled and control images, resulting in very few data points during short stimuli. In 
combined sequences, the inherently low SNR of ASL necessitates lower spatial resolution to 
achieve enough signal to quantify CBF. In dual-echo ASL-BOLD acquisitions, an early echo 
time is used to maximise sensitivity to a decaying label of blood, and a later echo time is 
selected to achieve greater BOLD-contrast weighting. Collecting data at 2 or more echo times 
places practical limits on when these echoes can occur and on the number of data points 
acquired in that time period (either in terms of voxel resolution or brain coverage). Both echo 
times are usually suboptimal, and both spatial resolution and brain coverage are less than 
could be obtained with a simple BOLD sequence. There is also cross-talk between the two 
datasets in a dual-echo approach: BOLD changes can contaminate the first CBF-weighted 
echo, and ASL tagging can remain in the second BOLD-weighted echo. This can be greatly 
mitigated by using a DEXI sequence instead (Schmithorst et al., 2014). Collecting 
simultaneous BOLD data and VASO estimates of CBV encounters similar concerns, as VASO 
requires a specific inversion time to null the blood signal and thus lengthens the sampling time 
of the combined sequence (Huber et al., 2017). 
  
Ultimately, the selection of acquisition schemes and specific imaging parameters cannot be 
undertaken blindly. Each decision can directly influence the accuracy and precision of the 
resulting physiological maps. In the next section, we will continue to explore the assumptions 
of our physiological models, and how variance and uncertainty can be identified and 
addressed. 
 
4.2   α 
  
As introduced in Section 2, the parameter α is a power-law coefficient describing the coupling 
between CBF and CBV. Grubb et al. (1974) assessed vascular responses to graded 
hypercapnia in anaesthetised rhesus monkeys using PET, observing a linear increase in total 
CBV with increasing CO2 partial pressure, and accompanying non-linear dependence of CBF, 
where CBV = 0.8CBFα, and α = 0.38. However, given that the BOLD signal arises 
predominantly from the venous compartment, in the context of calibrated fMRI, the Grubb 
constant may not be accurate as it accounts for total CBV. Indeed, a significantly lower 
coupling coefficient between CBF and venous CBV has been demonstrated using MRI and 
moderate hypercapnia (Chen and Pike, 2009), leading to many recent calibrated fMRI studies 
now assuming this lower value of α~0.23.  It should be noted that this value is specific to low-
intensity sensorimotor stimulation, with lower and higher values of α reported for low and high 
intensity visual stimuli, respectively (Chen and Pike, 2009).  
  
Detailed simulations have demonstrated that accurate determination of α is critical to the 
accuracy of estimates of the change in CMRO2 due to brain activity. An overestimation of α 
leads to an overestimation in calibration parameter M, and substantial underestimation in 
CMRO2, with greater error at larger changes in CMRO2 (Blockley et al., 2012; Griffeth and 
Buxton, 2011). By relaxing the physiological meaning of α and fitting it as a free parameter, 
Griffeth and Buxton (2011) found that α = 0.14 minimised error in CMRO2, which is in 
reasonable agreement with venous CBV-based experimental measures. Given that plausible 
lower α values are reported for calibrated fMRI, it is critical in future experiments to consider 
the potential influence of the experimental protocol when selecting which value to use. For 
example, Mark & Pike (2012) highlight the variability in α across hypercapnia and hyperoxia 
for both visual and motor tasks, and potential regional differences, particularly between cortical 
and subcortical structures, may need to be examined (Ances et al., 2008).  
 Whilst currently assumed values of α are based on normal physiological conditions, 
uncoupling of CBF and CBV have been observed in a range of diseases (Carrera et al., 2011; 
Ellika et al., 2007; Lacalle-Aurioles et al., 2014; Talati et al., 2015) as well as under 
anaesthesia (Kolbitsch et al., 2001), and in response to psychoactive stimulants (Luo et al., 
2009). Ideally, such uncoupling would be reflected by assuming an adjusted α in these 
populations, however, this is complicated by heterogeneity across the brain, and remains an 
area for future investigation.  
  
  
4.3   β 
  
The paramagnetic nature of dHb means that higher concentrations lead to an increase in the 
transverse relaxation rate (R2*=1/T2*). This relationship between susceptibility shift and change 
in R2* is characterised by the parameter β, which ultimately reflects the microvascular anatomy. 
Deriving this value requires detailed understanding of how protons in the extravascular space 
diffuse through the magnetic gradients that surround vessels, specifically whether they fall 
within static or diffusive dephasing regimes. Based on initial analytical models and Monte-
Carlo simulations, β = 1.5 was adopted for 1.5 T, with estimates bound between 1.0 and 2.0 
for small and large vessels respectively (Boxerman et al., 1995; He and Yablonskiy, 2007; 
Ogawa et al., 1993; Yablonskiy and Haacke, 1994). The vessel size limit, where the transition 
between dephasing regimes occurs, reduces as B0 increases (Kennan et al., 1994), such that 
β reduces at higher field strengths (typically β = 1.3 for 3 T and β = 1.0 for 7 T). 
  
Potential challenges with adopting these ‘standard’ values of β are that early modelling 
approaches did not fully account for intravascular signal, and later experimental validations 
(Driver et al., 2010; Murphy et al., 2013b; Rossi et al., 2012; van der Zwaag et al., 2009) did 
not account for changes in intravascular signal induced by experimental manipulation of CBV 
(Croal et al., 2017a). Furthermore, there is a dependency of β on echo time, a potential source 
of error that will vary with experimental protocol. There has been a recent shift towards 
linearising calibrated BOLD models (Blockley et al., 2015b; Griffeth et al., 2013), a 
simplification that has been shown to minimise error in OEF (Merola et al., 2016). By 
measuring ΔR2* in response to a graded isocapnic hyperoxia challenge, Croal et al. (2017) 
demonstrated experimentally that such an assumption may be appropriate across all field 
strengths, as a nonlinear regime can be sufficiently described as linear across the limited 
range of [dHb] seen in calibrated fMRI experiments. It is also plausible that β might also vary 
under conditions such as disease, if pathology were to disrupt microvascular/macrovascular 
distributions (such as may be seen in the chaotic vasculature in some tumours).  However, 
this remains a rather unexplored area.   
 
4.4   BOLD scaling parameter, M 
  
The BOLD scaling parameter, M, is one of the characteristic features of calibrated fMRI. 
Theoretically, M represents the maximum BOLD signal change that would occur if all of the 
deoxyhaemoglobin could be washed out of the venous blood vessels. Measuring M directly in 
this way would only be possible if CBF was sufficiently high or if oxygen metabolism could be 
suspended, which is implausible in practice. Therefore, calibration experiments generally only 
produce minor physiological perturbations that allow M to be estimated with the Davis model. 
As noted earlier, this most commonly consists of either a hypercapnic or hyperoxic gas 
challenge. Table 1 provides an overview of the expected effects of gas challenges on both 
physiological parameters and model constants in healthy volunteers when inspiring altered 
levels of CO2 or O2 at levels typically used in calibrated fMRI experiments. 
 
Hypercapnia challenges result in an increase in CBF and a decrease in venous [dHb]. Under 
the assumption that hypercapnia does not alter baseline CMRO2, the Davis model can be 
rewritten in terms of changes in the BOLD signal and CBF (Hoge et al., 1999). 
 
.                    !"#$%"#$%& = 𝑀 31 − ,-"0-"0&/:128.   (4) 
  
By rearranging Eq. 4 and combining the acquired BOLD and CBF measurements from a 
hypercapnia challenge, M can be estimated. As M is the change in T2*-weighted signal that 
would be caused by a total washout of dHb from the voxel, its amplitude is determined by 
properties of the tissue, the pulse sequence, and the amount of dHb present at rest: 
  
  𝑀 = 𝑇𝐸	𝐴		𝐶𝐵𝑉I	[𝑑𝐻𝑏]I2,      (5) 
  
where TE is the pulse sequence echo time and A is a field strength and sample-specific 
proportionality constant (Hoge et al., 1999). 
  
The discomfort experienced by some participants during hypercapnia prompted the 
development of the hyperoxia calibration technique. In contrast to hypercapnia, hyperoxia is 
imperceptible to participants and reduces dHb content by increasing the amount of O2 carried 
in the arterial blood plasma. In turn, more O2 remains bound to haemoglobin in the venous 
blood vessels, as the plasma O2 is preferentially consumed, resulting in a reduced [dHb]. 
Again, the Davis model can be rearranged to describe this experiment: 
  !"#$%"#$%& = 𝑀 31 − ,1 + ![=>?][=>?]&/28,     (6) 
  
leaving us with an unknown change in venous [dHb] (Δ[dHb]). Fortunately, this can be 
estimated from measurements of the participant’s PETO2, assuming equivalence with PaO2, 
using a gas analyser. Given this information it is possible to estimate the change in 
deoxyhaemoglobin concentration, ∆[dHb], (Blockley et al., 2015b; Chiarelli et al., 2007), 
  𝛥[𝑑𝐻𝑏] = −N[>?]OPQ#6RSOTQ#6N ,          (7) 
  
where SaO2 is the arterial blood oxygen saturation (Severinghaus, 1979), [Hb] is the 
haemoglobin concentration ([Hb] ≈ 0.03 x Hct), ϕ is the oxygen carrying capacity of 
haemoglobin and ε is the solubility coefficient of oxygen in blood. However, the resting 
deoxyhaemoglobin, [dHb]0, is unknown as it relies on a prior knowledge of the OEF (assuming 
SaO2=1): 
  
.                      [𝑑𝐻𝑏]I = [𝐻𝑏]	𝑂𝐸𝐹,              (8) 
  
Therefore, in order to estimate M in a hyperoxia calibration experiment using Eqs. 6 and 7, a 
value of OEF must be assumed. For a healthy population of participants, it may be reasonable 
to assume a single value of OEF. However, when comparing with an unhealthy cohort or an 
inherently heterogeneous group this may be a poor assumption as the hyperoxia calibration 
method does not cope well with such variance. Similarly, incorrect assumptions regarding Hct 
and SaO2 can negatively impact calibration via hyperoxia or combined hypercapnia-hyperoxia 
experiments. 
  
Parameter Hypercapnia Hyperoxia 
CBF Increase  
(Ito et al., 2008) 
Decrease/No change† 
(Floyd et al., 2003, Croal et al., 2015) 
 
CBV Increase (arteries only) 
(Ito et al., 2005) 
Decrease/No change† (arteries only) 
(Kolbitsch et al., 2002, Croal et al., 2015) 
 
OEF Decrease 
(Lin et al., 2013) 
Decrease 
(Faraco et al., 2015b) 
 
CMRO2 Decrease/No Change 
 (See Table 2) 
Decrease/No change 
(Sicard and Duong, 2005) 
 
α Decrease 
(J. Jean Chen and Pike, 2010) 
No Change 
(Faraco et al., 2015b) 
 
β No Change* No Change* 
 
BOLD Signal Increase 
(Mandell et al., 2008) 
Increase 
(Losert et al., 2002) 
 
ASL: Perfusion Increase 
(Noth et al., 2006) 
Decrease/No Change† 
(Bulte et al., 2007a) 
 
Blood T2 Increase (veins only) 
(Kettunen et al., 2002) 
No change 
(Kettunen et al., 2002) 
 
Blood T1 No change 
(Faraco et al., 2015b) 
Decrease (arteries only) 
(Kettunen et al., 2002) 
 
Blood T2* Increase (veins only) 
(Faraco et al., 2015b) 
Increase (veins only) 
(Faraco et al., 2015b) 
 
[dHb] Decrease 
(Hoge et al., 1999) 
Decrease 
(Driver et al., 2014) 
 
SaO2 No change 
(Faraco et al., 2015b) 
Increase (slight) 
(Faraco et al., 2015b) 
 
SvO2 Increase 
(Faraco et al., 2015b) 
Increase 
(Faraco et al., 2015b) 
 
* Assumed (See section 4.3) 
† Contributing effects of hypocapnia for non-isocapnic stimuli 
 Table 1. Indication of the impact on physiological and model parameters in healthy 
subjects of altering the inspired fractions of carbon dioxide or oxygen to levels 
commonly used for calibration. Hypercapnia and hyperoxia refer to FiCO2 ~0.05 and 
FiO2 ~0.5, respectively. 
 
 
Hct typically ranges between 36-54% (Billett, 1990), with natural fluctuations arising as a 
function of age, (Adeli et al., 2015; Daniel, 1973) and potentially race (Beutler and West, 2017; 
Cheng et al., 2004). The need for individualised knowledge of Hct becomes critical in anaemia, 
with significant reductions observed in a wide range of pathology (Babitt and Lin, 2012; 
Goodnough et al., 2003; Muncie and Campbell, 2009; Rees et al., 2010; van Iperen et al., 
2001), secondary to therapy (Groopman and Itri, 1999; Ludwig et al., 2004; Rodgers et al., 
2012), and in response to poor nutrition (Baker and Demaeyer, 1979). Both invasive and non-
invasive methods exist for Hct quantification, with the typical clinical approach being a packed-
cell volume test as part of a complete blood count (thus requiring a blood sample). Whilst this 
is the most efficient and accurate, there are circumstances where this may not be desirable 
from either a medical (e.g. neonatal subjects) or ethical perspective (e.g. healthy control 
studies). Potential alternatives include a multi-wavelength spectrophotometric method called 
co-oximetry, or an MR-derived measure that utilises the linear dependence of T1 on Hct, 
however both remain susceptible to error (Joseph et al., 2016; Li et al., 2017). Furthermore, 
Hct is known to be reduced in microvasculature in comparison to larger vessels. This can be 
addressed by assuming a lower uniform Hct value of ~0.25  (Calamante et al., 2016), however 
regional variation in Hct  (Okazawa et al., 1996) may still contribute variance, and pathologies 
such as haemodialysis and ischaemia may further disrupt vascular anatomy (Mchedlishvili 
and Varazashvili, 1987; Mitra et al., 2004).  
  
Arterial oxygen saturation (SaO2) represents the percentage of haemoglobin molecules 
saturated with oxygen in the arteries, which is typically 95-100% for healthy subjects under 
normal conditions. Assuming fully oxygenated arterial blood (SaO2 = 100%) is appealing and 
commonly done, as it simplifies much of the modeling and estimation of Δ[dHb], OEF and 
CMRO2. While Blockley et al. (Blockley et al., 2015b) demonstrated that for the generalised 
calibration model (Gauthier and Hoge, 2012b) this simplification could lead to potential errors 
across all three parameters, in practice, this error is negligible across normoxic ranges. 
However under hypoxic conditions, this would lead to potential underestimation of Δ[dHb], and 
overestimation of OEF and CMRO2 (Blockley et al., 2015b). In clinical cohorts where 
significant reductions in SaO2 (desaturation) are expected, it may be important to empirically 
measure this value. While the gold-standard technique is multi-wavelength co-oximetry and 
blood sampling, SaO2 is most commonly estimated using a pulse oximeter, which offers a non-
invasive (and often MR-compatible) transcutaneous approach but remains influenced by 
probe positioning and limb temperature (Schramm et al., 1997). SaO2 can also be inferred 
from PaO2 via the modified Hill’s equation (Severinghaus, 1979), and PaO2 can in turn be 
estimated from end-tidal O2 measurements throughout scanning. 
 
Assuming that this variability can be accounted for, is M simply a scaling factor in our 
calibration or is it ultimately useful in understanding an individual’s physiology? It is sensitive 
to multiple aspects of physiology, including resting venous CBV, [dHb], and vessel size 
through 𝛽. It is also sensitive to multiple aspects of the MRI acquisition, echo time, magnetic 
field strength, and the difference in magnetic susceptibility between oxygenated and 
deoxygenated haemoglobin (Hare et al., 2015). This has led to a wide range of reported M 
values, in addition to high test-retest variability (Lajoie et al., 2016). Therefore, we consider M 
to be a useful model parameter and critical to calibration, but not a derived image that can be 
interpreted in our multiparametric physiological experiment. 
 
4.5 Effect of gas challenges 
 
A crucial assumption of the calibrated fMRI model is that the gas challenges we administer to 
induce BOLD, CBF, and CBV changes are isometabolic, meaning they will not influence the 
CMRO2 values we wish to measure. However, there is evidence that hypercapnia challenges 
can alter metabolism and brain activity patterns (Hall et al., 2011; Xu et al., 2011), and even 
small resting fluctuations in CO2 levels are associated with neural changes (Driver et al., 
2016). Ultimately, there remains debate over whether the levels of hypercapnia typically 
achieved in calibrated fMRI experiments have a meaningful effect on CMRO2 estimates, and 
whether this can be corrected for (Bulte et al., 2012). A summary of the relevant literature is 
provided in Table 2. 
  
CMRO2 Measurement Cohort Effect of 
Hypercapnia 
on CMRO2 
Further Details 
    
Kety-Schmidt Technique 
(Kety and Schmidt, 1948)  
Humans No change No significant change with 5% or 7% CO2 inhalation 
PET 
(Rhodes et al., 1981) 
Dogs No change No significant change with +20–100 mmHg ΔPETCO2  
Radioactive Microspheres  
(Hoffman et al., 1982) 
Sprague-Dawley 
Rats 
No change No significant change with +20 mmHg ΔPETCO2 
Radioactive Microspheres 
(Barzilay et al., 1985) 
Dogs No change No significant change with +35 mmHg ΔPETCO2 
Kety-Schmidt Technique 
(Horvath et al., 1994) 
Male Fisher 
Rats 
Increase 60% increase with severe (+22 mmHg ΔPETCO2) 
hypercapnia  
Optical Imaging, LDF 
(Jones et al., 2005) 
Female Hooded 
Lister Rats 
Mixed No significant change with 5% CO2 inhalation, significant 
increase (~30%) with 10% CO2 inhalation 
EEG 
(Jones et al., 2005) 
Female Hooded 
Lister Rats 
Mixed No significant change with 5% CO2 inhalation, significant 
cortical desynchronisation with 10% CO2 inhalation 
Calibrated fMRI 
(Sicard and Duong, 2005) 
Male Sprague-
Dawley Rats 
Mixed No significant change with 5% CO2 inhalation, significant 
decrease with 10% CO2 inhalation 
Local Field Potentials 
(Zappe et al., 2008) 
Macaques Decrease 15% decrease in beta and gamma frequency bands with 
6% CO2 inhalation 
Kety-Schmidt Technique 
(Chen and Pike, 2010) 
Humans No change No significant change with mild (+4.7mmHg ΔPETCO2) or 
moderate (+9.0mmHg ΔPETCO2) hypercapnia 
TRUST MRI 
(Jain et al., 2011) 
Humans No change No significant change with 5% CO2 inhalation 
TRUST MRI 
(Xu et al., 2011) 
Humans Decrease 13.4% ± 2.3% decrease with inhalation of 5% CO2; linear 
relationship between ΔCMRO2 and ΔPETCO2 
EEG 
(Xu et al., 2011) 
Humans Mixed Power significantly increased in delta band, decreased in 
alpha band with 5% CO2 inhalation 
MEG 
(Hall et al., 2011) 
Humans Decrease Spatially-varying reduction in oscillatory power in alpha, 
beta, low gamma bands with +6.7 ± 0.7 mmHg ΔPETCO2 
MEG 
(Thesen et al., 2012) 
Humans Decrease Significant decrease in power in gamma band with 5% 
CO2 inhalation 
DOT, Calibrated fMRI 
(Yucel et al., 2014) 
Humans No Change Significant correlation between M derived from these two 
techniques with +8 mmHg ΔPETCO2 
iTRUST MRI 
(Rodgers et al., 2015) 
Humans Mixed Significant 14.6% ± 3.6% reduction using TRUST; no 
change using susceptometry, with 5% CO2 inhalation 
MEG 
(Driver et al., 2016) 
Humans Decrease Decrease in oscillatory power in delta, alpha, beta, low 
gamma bands with +0–8 mmHg ΔPETCO2 
Calibrated fMRI 
(Driver et al., 2017) 
Humans Decrease Significant decreases of 1.5 ± 0.6%/mmHg (visual), 1.8 ± 
0.7%/mmHg (motor), 1.3 ± 0.4%/mmHg (other GM) 
TRUST MRI 
(Peng et al., 2017) 
Humans Decrease Decrease in oscillatory power in delta, alpha, beta, low 
gamma bands with 5% CO2 inhalation 
 Table 2: Literature demonstrating the variable effects of hypercapnia on CMRO2 as 
measured using both MRI and non-MRI techniques. 
 
The advent of the use of a hyperoxic stimulus for calibration introduced additional concerns 
about the potential impact of elevated O2 on metabolism and physiology. Using 
magnetoencephalography, Croal et al. (2015) observed a significant alteration in neuronal 
oscillations during hyperoxia at rest, albeit it of lower magnitude and more focal than 
hypercapnia. Studies using electroencephalography (EEG) have found a range of conflicting 
results, both at rest (Kaskinoro et al., 2010; Seo et al., 2007; Sheng et al., 2017a) and under 
activation (Sheng et al., 2017a; Smith and Strawbridge, 1974), which may in part reflect the 
limited spatial resolution of EEG. 
 
There are additional physiological confounds which may need to be accounted for in hyperoxia 
calibrated MRI, depending on stimulus type. A small reduction in CBF has been reported using 
a fixed inspired challenge, due to vasoconstriction caused by both increased PaO2 and 
concurrent mild hyperventilation (inducing hypocapnia) (Bulte et al., 2007). By maintaining a 
constant CO2 level during the hyperoxia challenge, it was found that the flow velocity in the 
internal carotid arteries was not altered, suggesting that hypocapnia may be the dominant 
cause of this vasoconstrictive effect (Croal et al., 2015). Adding a further complication, 
changes in PaO2 have a direct influence on the T1 of blood, impacting the decay of the tagged 
blood signal  (Silvennoinen et al., 2003; Tadamura et al., 1997). As the oxygen content of the 
blood plasma increases, T1 decreases resulting in overestimation of the absolute change in 
CBF (Bulte et al., 2007). Note that these issues become even more complex if using carbogen 
(a mixture of CO2 and O2, with CO2 fractions typically ranging from 2 to 10%), or any 
combination of altered CO2 and O2 (Hare et al., 2013), but can be minimised with isocapnic 
hyperoxia (Croal et al., 2015). 
  
Initially, the SNR of ASL sequences was barely capable of detecting this small negative flow 
change. Thus, when using the model, it was usual to assume a degree of reduced flow in CBF 
rather than to rely on the ASL measured values. With advances in ASL acquisition, it is 
becoming possible to quantify small CBF changes and even AAT changes during hyperoxia 
calibration. T1 effects can potentially be estimated using known relationships between arterial 
oxygenation and relaxation times from the literature (Zhao et al., 2007). Ultimately, when 
selecting a strategy for quantifying CBF for calibrated fMRI, it is important to understand the 
assumptions of that approach and whether the gas challenges will require additional correction 
steps. 
  
Finally, the calibrated fMRI experiment also benefits greatly from long, steady-state periods of 
gas challenges. Unavoidable transients or resting fluctuations in arterial gas levels in addition 
to the intended gas stimulus paradigm will add noise to our acquired fMRI data, and ways to 
characterise and minimise these effects will boost the sensitivity and accuracy of calibration. 
There is substantial ongoing effort to induce stable changes in arterial gas tensions, 
independent of changes in the participant’s ventilatory patterns (Slessarev et al., 2007; Wise 
et al., 2007). 
 
5.      Derived parameters 
 
In the analysis of calibrated fMRI data, the acquired images described in Section 3 are 
combined using the Davis Model (Section 2), with careful attention paid to the model 
parameters and assumptions described in Section 4. The result is maps of new physiological 
parameters that cannot be measured directly, but that have clear clinical relevance in 
understanding brain health. 
 
5.1   OEF 
  
The OEF is simply the fraction of haemoglobin-bound oxygen that is extracted from the blood 
during its transit through the capillaries. It is defined as: 
  𝑂𝐸𝐹 = ,PX#61PY#6PX#6 /,  (9) 
where SaO2 is the arterial blood oxygen saturation (incoming blood oxygenation) and SvO2 is 
the venous blood oxygen saturation (outgoing blood oxygenation). As already discussed, 
SaO2 is often assumed to be 1 in healthy subjects with FiO2>0.2, but can be measured for 
greater accuracy.   
 
Whole-brain measures of OEF can be obtained with MRI (Lu and Ge, 2008). However, 
obtaining regional maps is more challenging. As described in Section 2, conventional 
calibrated fMRI experiments using a single hypercapnic or hyperoxic calibration do not contain 
sufficient information to estimate OEF. However, dual calibrated fMRI methods, which involve 
administering both O2 and CO2 gas challenges, enable measurement of baseline OEF that 
can then be combined with CBF maps to achieve quantitative maps of resting CMRO2 (see 
section 5.2).  Three major variants of dual calibrated fMRI exist, however, with differences in 
the implementation of the model fitting and parameter estimation leading to key differences in 
error and noise propagation. 
  
The simplest approach involves the serial calculation of each model parameter (Bulte et al., 
2012), resulting in a weighting of error towards the last parameters calculated, i.e. baseline 
OEF and baseline CMRO2. This approach means that images from the early stages of 
calculations have the highest SNR, but those at the end of the process (and arguably the most 
interesting) have the lowest. Another issue with this approach is that decisions about the 
analysis have to be made at each step. For example, should any of the data be smoothed, 
and if so, when and by how much? Data obtained from this method are shown in Figure 2. 
Other groups took a more simultaneous approach to the calculations (Gauthier and Hoge, 
2012b; Wise et al., 2013): the total amount of noise in the data is the same, but it is distributed 
more evenly, resulting in a higher SNR in the derived baseline OEF (or CMRO2) image. 
 
Whilst a detailed description of these data analysis approaches is beyond the scope of this 
review, here, an illustration of the basic principles is presented. A greater insight can be gained 
by considering a simplification of the approach proposed by Bulte et al. (2012). Under the 
assumption β=1, Eq. (4), describing the hypercapnia (HC) calibration experiment, can be 
rewritten in the following way, substituting Eq. (5) for M: 
 !"#$%Z["#$%& = 𝑇𝐸	𝐴	𝐶𝐵𝑉I	[𝑑𝐻𝑏]I\]]]]]^]]]]]_4 )1 − ,-"0Z[-"0& /:1`9,  (10) 
 
Given measurements of the change in BOLD and CBF, we can produce a signal that is 
sensitive to the product of CBV0 and [dHb]0 (plus some constants). Using a similar approach 
Eq. (6) describing the hyperoxia (HO) calibration experiment can be rewritten as 
 !"#$%Za"#$%& = −𝑇𝐸	𝐴	𝐶𝐵𝑉I	𝛥[𝑑𝐻𝑏].  (11) 
 
At first glance this looks significantly different to Eq. (6). However, it demonstrates the 
insensitivity of the hyperoxia experiment to [dHb]0 (and hence OEF via Eq. (8)). This also 
explains the need to assume a value for OEF in conventional calibrated fMRI using hyperoxia. 
Importantly, Eq. (11) demonstrates that the BOLD signal change in response to hyperoxia is 
CBV0 weighted. Given a BOLD measurement and an estimate of Δ[dHb] (see Eq. (7)), the 
signal can be sensitised to CBV0 (plus some constants). Finally, by taking the ratio of Eq. (10) 
and (11), and rearranging for [dHb]0, it can be seen that these constants do not need to be 
known (Blockley et al., 2015b): 
 
[𝑑𝐻𝑏]I = 3bcadeZ[cade& 83bcadeZacade& 8	 O[=>?]&)`13[cfZ[[cf& 8ghi9.  (12) 
 
This simplified dual calibrated fMRI model highlights the roles that hypercapnia and hyperoxia 
challenges play. The hypercapnia BOLD signal is sensitive to both CBV and [dHb], whilst the 
hyperoxia BOLD signal is sensitive to CBV alone, enabling [dHb] to be extracted and OEF 
calculated using Eq. (8). 
 
The dual calibrated fMRI approach, despite variation in the order of calculations, results in 
quantitative images of baseline OEF using data collected with whole brain coverage at typical 
BOLD resolutions in under 20 minutes. Although more complex than single gas calibrated 
fMRI in terms of both experiment design and modeling, knowledge of baseline OEF (and 
CMRO2) has greater clinical potential, for both understanding pathophysiological alterations 
and treatment monitoring (De Vis et al., 2015; Lajoie et al., 2017). 
  
5.2   CMRO2 
  
Oxidative metabolism is necessary to meet the vast majority of the brain’s energetic demands, 
and therefore believed to be the physiological parameter most tightly coupled to the activity of 
the brain (Du et al., 2008; Hyder, 2010). Hence CMRO2 is an important biomarker for 
cerebrovascular health, providing the best measure of either resting activity or relative 
changes during periods of increased activity.  
 
Relative changes in CMRO2 can be obtained from a conventional calibrated fMRI scan based 
on the Davis model (Eq. 2). Although much of the research on relative CMRO2 has focused 
on validation within healthy populations, there is demonstrated utility under disrupted 
physiology such as in ageing (Mohtasib et al., 2012), multiple sclerosis (Hubbard et al., 2017) 
and HIV (Ances et al., 2011). 
  
In addition to characterising relative changes in metabolism, quantitative measures of tissue 
metabolism at rest may provide an important clinical biomarker. Resting CMRO2 at baseline 
is essentially defined from Fick’s principle that the oxygen delivered to a region minus the 
oxygen departing that region must be the amount of oxygen left behind and consequently 
metabolised. Thus, to calculate resting CMRO2 we need to know resting CBF (the rate of blood 
delivery), resting OEF (the fraction of oxygen extracted for metabolism), and the oxygen 
carrying capacity of blood (CaO2), which can be inferred from Hct. 
  𝐶𝑀𝑅𝑂k = 𝐶𝐵𝐹	𝑂𝐸𝐹	𝐶Q𝑂k  (13) 
  
Thus, resting CMRO2 images can be produced by multiplying and scaling quantitative images 
of resting OEF and CBF.  
 
 
   
Figure 2. Single slice from an example dual calibrated fMRI dataset. Top left shows the 
high-resolution T1-weighted anatomical image. The CBF and AAT images were 
produced from a multi-PLD pCASL sequence, M was calculated from a hypercapnia 
stimulus, OEF was determined from M and the BOLD response to a hyperoxia stimulus. 
CBV was calculated from the BOLD response to hyperoxia. CMRO2 was calculated from 
CBF and OEF, and the CVR was calculated from the ASL response to hypercapnia. 
 
 
5.3   Cerebrovascular Reactivity 
  
Monitoring PETCO2 during BOLD or CBF imaging enables robust mapping of cerebrovascular 
reactivity (CVR), the vascular response to a vasoactive stimulus. Routinely assessed in large 
vessels using TCD and simple breath-holding techniques that cause transient hypercapnia 
(Müller et al., 1995), CVR provides insight into healthy or pathological vascular function. When 
CVR is acquired in the context of a calibrated fMRI experiment, it provides semi-quantitative 
or quantitative maps of %BOLD or %CBF increase per ∆PETCO2 (mmHg) throughout the brain.  
 
CVR maps are sensitive to regional vascular pathology in a range of diseases. In a recent 
review article, Juttokanda and Donahue present an excellent overview of the clinical CVR 
literature in cerebrovascular disease, highlighting the role of CVR imaging in studying arterial 
steno-occlusive disease, anemia, and small vessel disease (Juttukonda et al., 2017).  Special 
care needs to be taken when using ASL to quantify CVR in these patient cohorts, as many 
assumptions about the labelling efficiency or vascular transit times may be altered in the 
presence of widespread vascular pathology (as discussed in Section 3.2). 
  
Dementia is another key target for CVR research. In young healthy carriers of ApoE-e4, a 
genetic risk factor for Alzheimer’s Disease (AD), BOLD CVR has identified haemodynamic 
impairment in specific brain regions associated with memory (Suri et al., 2015).  In older 
patients with AD, altered regional CVR has been observed to correlate with cognitive function 
as assessed by the Mini Mental State Examination (Richiardi et al., 2015). 
 
In healthy aging, CVR changes may also precede radiological and cognitive symptoms of age-
related white matter disease. After observing that areas of reduced CVR in healthy young 
individuals corresponded to regions of high white matter lesion frequency in the elderly, Sam 
and colleagues tested this relationship longitudinally, demonstrating that reduced CVR 
preceded the formation of white matter hyperintensities (Sam et al., 2016). CVR is also 
reduced in Multiple Sclerosis (MS), and this vascular impairment is correlated with grey matter 
atrophy and lesion volume (Marshall et al., 2014). Although typically viewed as a 
neuroinflammatory disease, these observations may indicate that haemodynamic impairment 
contributes to concurrent widespread neurodegeneration in MS. CVR is an exciting technique 
for monitoring and potentially predicting local tissue damage, and evaluating haemodynamic 
function in a range of diseases and at-risk groups. 
  
There is an ongoing effort to standardize the acquisition and reporting of CVR maps, as the 
international community has reported using numerous gas delivery protocols and imaging 
parameters that may not be directly comparable (Moreton et al., 2016). However, CVR is 
poised to become a clinical tool, as safety concerns are addressed (Spano et al., 2013) and 
clear targets for influencing clinical outcomes are identified (Smeeing et al., 2016). The CVR 
field has developed bespoke gas stimuli to efficiently probe different aspects of the vascular 
dilatory response, such as sinusoidal (Blockley et al., 2017) or ramped (Bhogal et al., 2014) 
delivery of hypercapnia, and it remains to be seen whether these techniques will be 
incorporated into calibrated fMRI experiments. 
 
 
6.      Utility of multiparametric physiologic imaging 
 
We have thus far examined the numerous physiological parameters that can be extracted in 
the context of a calibrated fMRI experiment, including BOLD, CBF, CBV, CVR, OEF, and 
CMRO2 (e.g., Figure 2), but what is ultimately the benefit of achieving such multiparametric 
data? 
  
In a study of traumatic brain injury (TBI), multiparametric physiological imaging data acquired 
within 72 hours of injury using 15O PET were used to predict irreparable tissue damage 
(Cunningham et al., 2005). Although healthy thresholds for each parameter could be 
estimated, the study showed that multivariate analysis combining CBF, OEF, and CMRO2 
could better predict lesion formation. The authors state:  
“It is important to emphasize that […] none of the physiological variables alone can be 
used to define acutely the extent of irreversibly damaged tissue. […] Future attempts 
to produce predictive maps for tissue outcome may require using combinations of the 
physiological variables.”  
In this paper, we have highlighted MRI techniques for achieving multiparametric physiological 
data in the context of a calibrated fMRI experiment; we propose that these data will become 
increasingly important for accurately and precisely characterising neurovascular health in a 
range of clinical applications. 
The following examples demonstrate that combining information across vascular and 
metabolic imaging metrics may pave the way for improved diagnosis in diseases with similar 
clinical presentations, enable staging of disease severity based on imaging metrics, and allow 
better development and targeting of treatment therapies. 
 6.1 Stroke 
 
Stroke is perhaps the most immediate candidate for multiparametric physiological imaging, as 
numerous haemodynamic changes occur concurrently with neural pathology and cognitive 
symptoms. 
  
In the early stages of haemodynamic failure, autoregulatory compensation enables successful 
maintenance of CBF during a decrease in perfusion pressure via increases in CBV. As the 
limit of vasodilation (CBV) is reached and CBF is slightly reduced, an increase in OEF 
maintains normal CMRO2 (Powers, 1991); this stage is referred to as oligaemia. Eventually 
CBF is no longer sufficient, OEF is maximised, and CMRO2 is affected as acute damage is 
done to ischaemic brain tissue. By measuring CBF, CBV, OEF and CMRO2 in a 
multiparametric experiment, we can potentially stage the haemodynamic risk or damage to 
regional brain tissue. 
  
Numerous studies in the literature have used 15O PET to examine how combinations of 
physiological parameters can be used to assess subsequent risk to regional brain tissue in 
stroke. In a study of unilateral carotid artery occlusion, patients with increased OEF and CBV 
had higher risk of ischaemic stroke than those with increased OEF and normal CBV, 
suggesting more severe haemodynamic compromise, perhaps linked to exhausted 
autoregulatory vasodilation (Derdeyn et al., 2002). Reduced CBF and normal CVR may 
characterize oxygen hypometabolism, potentially due to ischemia-related neuronal loss 
(Kuroda et al., 2004) which may indicate that such ischemic lesions are not critically 
compromised from a haemodynamic perspective and are at low risk for subsequent stroke. 
Observations of normal CBF and reduced CVR may also reflect good prognosis (Isozaki et 
al., 2010). A negative correlation is observed between CVR and OEF in patients with occluded 
carotid arteries, potentially reflecting a continuous transition of tissue from normal conditions 
to increasing ischemic stress and beyond (Nemoto et al., 2004). However, the authors note 
key discrepancies in this relationship, and suggest that “OEF alone may not be capable of 
identifying the true spectrum of patients at increased stroke risk.” These results from PET 
literature clearly demonstrate the promise of multiparametric imaging approaches to 
understanding the complex haemodynamic changes in stroke, and the MRI methods 
presented in this paper could be used to make such measurements more accessible and 
repeatable in routine clinical practice. 
  
Multiparametric physiological imaging may also improve our ability to plan treatment in stroke. 
In a study in rats, resting CBF and CVR were initially elevated in the peri-lesional cortex at 7 
days post-infarct by 60% and 80%, respectively (Lake et al., 2017). However, by 21 days after 
stroke, this CBF effect was resolved whereas CVR remained elevated. By combining CBF and 
CVR mapping of the peri-infarct zone in the weeks following an ischaemic insult, the authors 
suggest an extended temporal window for therapeutic interventions may be identified. In 
humans, CVR mapping in stroke has allowed compensatory flow patterns and vascular steal 
to be studied (Faraco et al., 2015a; Poublanc et al., 2013; Sobczyk et al., 2014). 
Multiparametric information has also been used to aid surgical planning and to monitor the 
effects of interventions in stroke (Donahue et al., 2017). 
  
After stroke, imaging can also be used to monitor recovery of both haemodynamic and 
cerebral function. While CBV and CBF measures can identify angiogenesis, CVR can assess 
whether the newly generated vasculature is functionally capable. Therapeutic interventions 
can be administered to induce angiogenesis in specific brain regions: for example, exercise 
has been shown to increase CBV in the motor cortex of rats. Furthermore, whereas baseline 
CBF was maintained, CVR during hypercapnia was elevated in these regions, indicating that 
the exercise therapy increased the size of the capillary reserve (Swain et al., 2003). Finally, 
combining baseline measures of CMRO2 with functional BOLD changes during a stimulus can 
identify where vascular plasticity is directly fostering neural plasticity (Seevinck et al., 2010). 
Multiparametric imaging can thus play an important role in assessing the success of 
therapeutic interventions. 
 
 
6.2  Multiple Sclerosis 
 
Calibrated fMRI experiments have already been used successfully to study Multiple Sclerosis 
(MS), demonstrating a clear link between functional CMRO2 changes and fatigue and 
neurological disability across patients (Hubbard et al., 2017). With this demonstration of 
calibrated fMRI as a practical and informative technique in this cohort, and with evidence from 
the literature that numerous haemodynamic factors may contribute to or be affected in MS, 
we assert that multiparametric physiological data will greatly improve our understanding of the 
vascular contributions to this primarily neuroinflammatory and neurodegenerative disease. 
  
For example, imaging haemodynamic changes may help track lesion formation and evolution. 
In an animal model of MS, lesion formation and BBB disruption are preceded by elevated CBV 
in the nearby tissue (Broom et al., 2005). In humans, active (contrast-enhancing) lesions also 
demonstrate approximately 25% increases in CBV and CBF, and these haemodynamic 
changes are detectable prior to BBB breakdown or changes in tissue integrity (Ge et al., 2005; 
Wuerfel et al., 2004). This inflammatory vasodilation subsides over time and ultimately 
reverses: chronic lesions that persist beyond the acute inflammatory period exhibit reductions 
in CBV and CBF. Finally, these haemodynamic changes extend far beyond the focal lesion, 
affecting substantial areas of nearby tissue (Bester et al., 2015). 
  
Many of these studies primarily relied on DSC imaging to measure CBF and CBV in humans, 
however these techniques may not be appropriate for regular, repeated imaging of 
haemodynamics in longitudinal studies. The Gadolinium-based contrast agents used in DSC 
acquisitions have recently been observed to accumulate in the brain in a dose-dependent 
manner (McDonald et al., 2015), and thus the imaging techniques used in calibrated fMRI (i.e., 
BOLD, ASL, VASO), which do not involve injection of these contrast agents, may be preferable 
to study acute vascular changes during periods of active disease. 
  
CVR, OEF, and CMRO2 (baseline) have also been shown to be reduced in MS across the 
brain (by approximately 30%, 14%, 23%, respectively), and these metrics appear to be 
associated with lesion load and atrophy measures (Ge et al., 2012; Marshall et al., 2014). 
Further characterisation of this impairment could elucidate whether CVR impairment or 
hypometabolism have a causal role in grey matter thinning or widespread neurodegeneration. 
 
 
6.3  Alzheimer’s Disease and Dementia 
 
Characterisation of multiple haemodynamic factors may assist diagnosing and tracking the 
progression of Alzheimer’s Disease (AD). In a comparison of patients with AD, patients with 
mild cognitive impairment who would later convert to AD, and healthy controls, CBV changes 
were observed only in the late-stage AD cohort whereas CBF impairment was observed earlier 
in disease progression (Lacalle-Aurioles et al., 2014). Impaired CVR has also been observed 
in young healthy subjects with increased genetic risk of developing AD (Suri et al., 2015). 
Thus, CBF and CVR mapping may offer early windows for understanding disease 
mechanisms, before changes in CBV or overt cognitive function develop. 
  
It is also important to differentiate AD from other types of dementia (e.g., vascular or fronto-
parietal dementias). Lajoie and colleagues observed patterns of reduced CBF and CMRO2 
that were specific to parieto-temporal brain regions known to be impaired in AD (Lajoie et al., 
2017). When combined with unimpaired frontal CBF and normal whole-brain grey matter CVR, 
the researchers could more confidently assert that the observed pathology was associated 
specifically with AD rather than generalised vascular disease. Similarly, in a study directly 
comparing AD with vascular dementia, the combination of CBF and CVR mapping was 
sensitive to differences in pathological haemodynamics between the cohorts (Gao et al., 
2013). 
 
 
6.4 Drug effects 
 
It is essential that multiple haemodynamic and metabolic parameters are characterised in drug 
studies. For example, sildenafil is a candidate treatment for AD patients; using MRI, a 50 mg 
dose was shown to increase CBF and CMRO2 throughout the brain, with most pronounced 
CBF increases in bilateral medial temporal cortex, whereas CVR was decreased (Sheng et 
al., 2017b). Anaesthestic drugs also have numerous physiological consequences: both 
baseline and task-induced changes in CBF are reduced following low-dose sevoflurane, and 
the relationship between functional BOLD and CBF changes is impacted in a spatially non-
uniform manner (Qiu et al., 2008). 
  
In a dual calibrated fMRI experiment, Merola and colleagues explored the effects of caffeine, 
a common drug that may influence and add variability to functional imaging datasets in many 
studies (Merola et al., 2017). Compared to placebo, caffeine increased OEF (15.6%) and 
decreased CBF (-30.4%) and CMRO2 (-18.6%) in healthy volunteers. Whereas the CBF effect 
was widespread throughout the brain, the metabolic changes were more localised to the 
frontal gyrus, parietal and occipital lobes. This study demonstrates the ability of calibrated 
fMRI experiments to map the vascular and metabolic effects of caffeine, and provides 
evidence that caffeine use (acute and chronic) should be considered and controlled in imaging 
studies when possible. 
 
More generally, functional imaging studies to understand brain function during anaesthesia or 
following administration of a drug or medication must consider how neurovascular coupling 
relationships are affected, and calibrated fMRI studies will better identify which physiological 
parameters are truly being modulated in these cases.  
 
 
7.      Considerations and Opportunities 
 
7.1      Validation 
  
All data acquired in a calibrated fMRI experiment can be dramatically altered by changes in 
the imaging parameters or analysis procedures. However, CBF, CBV, OEF, CMRO2, and CVR 
(in terms of flow changes) are ultimately quantifying true human physiology that has been 
studied for centuries using a broad range of techniques. We have a body of literature that can 
provide estimates of these values in healthy humans and in specific cohorts, and many 
aspects of calibrated fMRI have been independently validated against other imaging 
modalities in a limited number of patient groups as well as with healthy subjects. The validation 
of calibrated fMRI is considered elsewhere in this issue and so will only be briefly considered 
here (see article by Wise et al. in this issue). 
 
The use of different variants of ASL to measure CBF have been validated against PET (Fan 
et al., 2016), perfusion CT (Koziak et al., 2008), and transcranial Doppler Ultrasound (TCD) 
(Croal et al., 2017b). The primary clinical tool for measuring CVR in patients is TCD, and the 
most common vasoactive stimulus used is a short breath hold, although acetazolamide is 
often used in clinical settings to provide a more dramatic dilation effect. Both ASL and BOLD 
MRI have been used to measure CVR in patients (Smeeing et al., 2016) and healthy subjects 
(Zhou et al., 2015), and have been shown to correlate well. CBV has typically been measured 
with MRI using contrast enhanced methods involving the injection of a gadolinium-based 
contrast agent, which have in turn been validated in patients against SPECT methods (Engvall 
et al., 2008). The non-invasive MR method VASO has been validated against PET (Uh et al., 
2011). OEF and CMRO2 can be measured using triple oxygen (15O) PET, however the recent 
MRI methods for obtaining these parameters are yet to be validated against this modality. 
OEF information can also be obtained from near infrared spectroscopy (NIRS), however this 
is a mixed arterial-venous signal and only provides information over large, diffuse regions and 
thus is difficult to use as a direct validation tool. 
   
Ultimately, the development of new physiological imaging parameters must be done with 
caution. There is constant risk of “fixing” acquisition procedures or “optimising” analysis 
pipelines such that the final numbers we achieve are within our expected, plausible limits as 
determined by gold-standard techniques or ranges published in the literature. As a field, we 
must be constantly sceptical of our credible results, and continue to push for confidence in our 
data through improved validation procedures. 
  
 
 
7.2   Calibration without gas challenges 
  
A multiparametric physiological imaging study of AD patients and healthy controls 
demonstrated the challenges encountered when administering gas challenges for calibrated 
fMRI in patient cohorts (Lajoie et al., 2017). During hypercapnic testing, 10 out of 59 patients 
(17%) and 6 out of 60 controls (10%) withdrew due to the feeling of anxiety caused by the CO2 
inhalation. Mask leakage affected a further 6 patients and 2 controls. Interestingly, the 
frequency of drop-out or other problems related to hypercapnia and mask leakage was 
attenuated as the study trial progressed, indicating that researchers became more skilled at 
fixing leaky face masks via repositioning or tape, and at identifying which participants were 
okay to continue with the gas protocol (potentially introducing bias). The authors also note that 
the lengthy testing and imaging protocol was performed during a single visit, and suggest that 
“future calibrated studies may consider planning for a separate day to perform the hypercapnia 
testing alone, thus reducing potential stress and fatigue experienced by the participants.“ 
However, this study demonstrates that many patients and healthy controls may not be able to 
complete a calibrated fMRI experiment, and thus it is desirable to develop alternative 
approaches for achieving similar physiological data without the use of gas inhalation 
challenges. 
 
In hypercapnic, hyperoxic, and dual calibration experiments, the physiological stimulus 
(modified gas inhalation) is used to physically reduce the amount of deoxyhaemoglobin 
present in the voxel, aiming to extrapolate to the condition where all dHb has been washed 
out of the venous blood. An alternative approach under development posits that we don’t 
actually need to wash out the deoxyhaemoglobin, and instead we only need to remove its 
effect on the signal we measure (Blockley et al., 2015). Since the BOLD effect is caused by 
the dephasing of the tissue signal due to the microscopic magnetic field gradients that 
surround deoxygenated blood vessels, a spin echo refocusing pulse should be able to recover 
some of this lost signal. This “lost signal” can be measured by the relaxometry parameter R2′, 
the reversible transverse relaxation rate. R2′ has previously been used to normalise stimulus 
evoked changes in R2* on the way to quantifying changes in CMRO2 (Fujita et al., 2006; Kida 
et al., 2000). More recently R2′ was placed in the calibrated fMRI framework by recognising 
that it is theoretically sensitive to the same physical and physiological components as M (c.f. 
Eq. 5), 
  𝑅kl = 𝐴	𝐶𝐵𝑉I	[𝑑𝐻𝑏]I2 	⇒ 	𝑀 = 𝑇𝐸	𝑅kl  .     (14) 
  
However, the effectiveness of spin echo refocusing is dependent on the scale of the magnetic 
field gradients (Boxerman et al., 1995). Therefore, simulations predict that the M measured 
via R2′ will be underestimated when compared with the hypercapnia M (Blockley et al., 2012b). 
This hypothesis was later confirmed experimentally (Blockley et al., 2015a).  
  
The R2′ weighted signal can also be used to estimate baseline OEF using the closely related 
“quantitative BOLD” technique (He and Yablonskiy, 2007). Whilst the calibrated fMRI 
technique operates in the monoexponential regime of the R2* signal, quantitative BOLD takes 
advantage of the additional information that is stored in the quadratic exponential decay. This 
quadratic exponential decay is revealed at low values of the spin echo displacement time, 𝜏, 
which is responsible for the degree of R2′ weighting included in the image. This short 𝜏 regime 
provides sensitivity to venous CBV, enabling OEF to be extracted from a measurement of R2′ 
(c.f. Eq. 8 and under the assumption β=1): 
  𝑂𝐸𝐹 = 56op	[>?]	-".& .   (15) 
 
This principle was proven early on (An and Lin, 2000; He and Yablonskiy, 2007) with recent 
work concentrating on reducing confounding effects (Stone and Blockley, 2017) and robust 
model fitting (Domsch et al., 2017). 
 
7.3   Future opportunities 
  
Even after advanced correction strategies, several noise sources will inevitably remain in the 
acquired data in a calibrated fMRI experiment (Murphy et al., 2013a). In some instances, we 
may be able to characterise a noise source, model its impact on our data, and reduce or 
remove these confounds. We may also uncover new ways to transform these sources of 
variance into additional insight into brain function. The pulsatility of vessels, typically 
considered a noise source, can be combined with CBV estimates to achieve maps of arterial 
compliance, which is a useful measure of arterial stiffness (Yan et al., 2016). Blood pressure 
will affect numerous aspects of vascular physiology, and new hardware developments for 
measuring beat-to-beat blood pressure during scanning may allow us to characterise the 
vascular response to blood pressure fluctuations (Baruch et al., 2011; Whittaker et al., 2016). 
Advances in this area could lead to whole-brain assessment of cerebral autoregulation, which 
is a critical clinical measurement in hypertension and stroke (Diedler et al., 2009; Jordan and 
Powers, 2012; Paulson et al., 1990). Similarly, recording fluctuations in vascular tone (via 
pulse wave velocity) or arousal (using the Galvanic Skin Response as a surrogate) during the 
calibrated fMRI experiment could lead to interesting new directions for physiological parameter 
mapping. 
  
Other sources of physiological variance may remain stable during the course of a single MRI 
scan session, but could add variance to a calibrated fMRI study when comparing individuals 
or cohorts. In a systematic review of factors contributing to CBF values, Clement and 
colleagues identified 58 factors that should be considered and/or controlled for in multi-centre 
ASL studies (Clement et al., 2017), grouped into four categories: a) physiology, lifestyle, and 
health, b) blood components, c) mental state, personality, and cognition, and d) drugs. Some 
parameters may be straightforward to control in a given study; for example, the time of day 
that scanning occurs could be fixed, the effect of meals or caffeine could be avoided via 
fasting, and smokers could be excluded. However, if smokers are the cohort of interest, it is 
important to use the complete multiparametric imaging power of calibrated fMRI to differentiate 
the vascular, metabolic, and neurovascular coupling changes in this cohort. 
  
For more subtle contributors of physiological variance, such as mood or stress levels, large 
datasets may be necessary to probe their relationship to the multiple physiological parameters 
being mapped. As open-access data sharing becomes more supported, we encourage 
imagers to record as much physiological information about their participants as possible, to 
help future studies capitalise on any untapped information in these rich datasets. 
 
 
8.      Conclusion 
 
Calibrating BOLD fMRI may seem daunting due to the requirement of additional hardware, 
pulse sequences, and analysis tools, as well as the additional “expertise” necessary to ensure 
the process goes smoothly. However, the added value of the extra physiological information 
that may be obtained, and the specificity and quantitation that enables the comparison of data 
between sessions, subjects, groups or sites, can more than compensate for this. As these 
techniques improve and become more commonplace, they will also benefit from further 
validation against more familiar modalities, and greater availability and reliability of the tools 
needed to perform the calibration. As with all neuroimaging, it is unlikely that there will ever 
be a calibration method that will work for every set of circumstances, however a variety of 
multiparametric methods will enable a researcher or clinician to select the approach that 
provides the most accurate and valuable diagnostic data specific to their needs. 
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